A single-center, randomized, controlled, open-label, crossover study in currently smoking adult participants to investigate the nicotine pharmacokinetics and pharmacodynamics of Tobacco Heating System (THS) with LEVIA, a tobacco-free nicotine-containing consumable, compared to THS with TEREA, a tobacco-containing consumable, and cigarettes. The study will use a 2-period, 2-sequence design for the ad libitum use days, and a 3-period, 6-sequence Williams design for the single-use days. Across the ad libitum use and single-use period, this is a design with 5 periods and 12 sequences.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Background-corrected plasma nicotine concentrations (cC0h) to (cC12h)
Timeframe: Measured from Day 3 to Day 5
Background-corrected maximum plasma nicotine concentration (Cmax)
Timeframe: Measured from Day 3 to Day 5
Area under the background-corrected plasma nicotine concentration-time curve (AUC) (AUC) from the start of product use (T0) to the timepoint of last quantifiable concentration (AUC0-last) and extrapolated to infinity (AUC0-infinity)
Timeframe: Measured from Day 3 to Day 5
Time to the background-corrected maximum concentration (Tmax)
Timeframe: Measured from Day 3 to Day 5
Terminal elimination rate constant (λz)
Timeframe: Measured from Day 3 to Day 5
Half-life of nicotine (t1/2)
Timeframe: Measured from Day 3 to Day 5